Minoshima Y - Search Results

1

Differences in Muscle Fatigability of Vastus Medialis between Sexes Using Surface Electromyographic Power Spectral Analysis in Healthy Adults.

Minoshima Y, Nishimura Y, Tsuboi H, Sato H, Ogawa T, Kamijo YI, Umezu Y, Tajima F. Minoshima Y, et al. Prog Rehabil Med. 2022 Sep 17;7:20220051. doi: 10.2490/prm.20220051. eCollection 2022. Prog Rehabil Med. 2022. PMID: 36188139 Free PMC article.

2

Differences in fatigability of vastus medialis muscle between patients with limb symmetry index of <90% and ≥90% after chronic anterior cruciate ligament reconstruction.

Sato H, Nishimura Y, Tsuboi H, Minoshima Y, Sakata T, Umezu Y, Tajima F. Sato H, et al. Among authors: minoshima y. Knee. 2021 Aug;31:39-45. doi: 10.1016/j.knee.2021.05.005. Epub 2021 Jun 7. Knee. 2021. PMID: 34111800

3

Case Report: A Rehabilitation Practice Report During ICU Management for a Patient With Multiple Disabilities Due to COVID-19 Pneumonia and COPD.

Kinoshita T, Kouda K, Umemoto Y, Yasuoka Y, Minoshima Y, Mikami Y, Nishimura Y, Miyamoto K, Kato S, Tajima F. Kinoshita T, et al. Among authors: minoshima y. Front Med (Lausanne). 2021 Jun 28;8:692898. doi: 10.3389/fmed.2021.692898. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34262919 Free PMC article.

4

Comparison of erector spinae fatigability between female patients with Parkinson's disease and healthy individuals: a cross sectional pilot study.

Nishimura Y, Tsuboi H, Murata KY, Minoshima Y, Sato H, Umezu Y, Tajima F. Nishimura Y, et al. Among authors: minoshima y. BMC Neurol. 2022 May 23;22(1):189. doi: 10.1186/s12883-022-02719-w. BMC Neurol. 2022. PMID: 35606705 Free PMC article.

5

Surface electromyographic activity of the erector spinae and multifidus during arm- and leg-ergometer exercises in young healthy men.

Shima D, Nishimura Y, Hashizaki T, Minoshima Y, Yoshikawa T, Umemoto Y, Kinoshita T, Kouda K, Tajima F, Kamijo YI. Shima D, et al. Among authors: minoshima y. Front Physiol. 2022 Nov 25;13:974632. doi: 10.3389/fphys.2022.974632. eCollection 2022. Front Physiol. 2022. PMID: 36505070 Free PMC article.

6

Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.

Motzer RJ, Porta C, Eto M, Hutson TE, Rha SY, Merchan JR, Winquist E, Gurney H, Grünwald V, George S, Markensohn J, Burgents JE, Cristescu R, Sachdev P, Narita Y, Huang J, Zhao Z, Okpara CE, Minoshima Y, Choueiri TK. Motzer RJ, et al. Among authors: minoshima y. Ann Oncol. 2024 Dec 11:S0923-7534(24)04978-0. doi: 10.1016/j.annonc.2024.12.003. Online ahead of print. Ann Oncol. 2024. PMID: 39672382 Free article.

7

Morphology of the egg-case and larva of Paracymus aeneus (Germar) (Coleoptera: Hydrophilidae).

Minoshima YN, Watanabe K. Minoshima YN, et al. Zootaxa. 2024 Nov 26;5541(2):200-214. doi: 10.11646/zootaxa.5541.2.5. Zootaxa. 2024. PMID: 39646151

8

Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium.

Eng JW, Kato Y, Adachi Y, Swaminathan B, Naiche LA, Vadakath R, Sakamoto Y, Nakazawa Y, Tachino S, Ito K, Abe T, Minoshima Y, Hoshino-Negishi K, Ogasawara H, Kawakatsu T, Nishimura M, Katayama M, Shimizu M, Tahara K, Sato T, Suzuki K, Agarwala K, Iwata M, Nomoto K, Ozawa Y, Imai T, Funahashi Y, Matsui J, Kitajewski J. Eng JW, et al. Among authors: minoshima y. Cancer Res Commun. 2024 Jul 1;4(7):1881-1893. doi: 10.1158/2767-9764.CRC-24-0081. Cancer Res Commun. 2024. PMID: 38984877 Free PMC article.

9

Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.

Makker V, Taylor MH, Aghajanian C, Cohn AL, Brose MS, Simone CD, Cao ZA, Suttner L, Loboda A, Cristescu R, Jelinic P, Orlowski R, Dutta L, Matsui J, Dutcus CE, Minoshima Y, Messing MJ. Makker V, et al. Among authors: minoshima y. J Immunother Cancer. 2024 Jan 19;12(1):e007929. doi: 10.1136/jitc-2023-007929. J Immunother Cancer. 2024. PMID: 38242717 Free PMC article.

10

Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti-PD-1 Antibody.

Niwa Y, Adachi K, Tabata K, Ishida R, Hotta K, Ishida T, Mano Y, Ozawa Y, Minoshima Y, Funahashi Y, Semba T. Niwa Y, et al. Among authors: minoshima y. Mol Cancer Ther. 2023 Apr 3;22(4):499-510. doi: 10.1158/1535-7163.MCT-22-0475. Mol Cancer Ther. 2023. PMID: 36696578 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters